All Press Releases
PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS
Malmö, 29 August 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space of the participation in a new podcast episode, released today August 29, 2025! CEO Gustav H. Gram, in light of the successful summer…
PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY – 30 JUNE 2025)
Malmö, 27 August, 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes the Company´s interim report for the period January - June 2025. The report can be found on the Company's website: https://pilapharma.com/financial-reports/ SUMMARY OF INTERIM REPORT First Half year (1 January -…
PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A
Malmö, 21 August 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, invites shareholders, investors and other stakeholders with interest in the space, to a live online interview and Q&A. CEO Gustav H. Gram will present online at 13:30 CEST on August 27, 2025, in connection…